Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.

Tadocizumab significantly inhibited ADP-induced platelet aggregation in vitro and completely blocked arachidonic acid-induced platelet aggregation. [1]
Tadocizumab also inhibited human platelet adhesion to von Willebrand factor, fibrinogen, fibronectin, and subendothelial matrix. [2]

Tadocizumab inhibits platelet aggregation in vitro in a dose-dependent manner. In rhesus monkeys, platelet aggregation was completely prevented by intravenous injection over 0.25 mg/kg or at an infusion rate of 1.5 μg/kg/min. In a photochemically induced thrombosis model in squirrel monkeys, intravenous injection of 1 mg/kg of Tadocizumab followed by a continuous infusion at a rate of 6 μg/kg/min for 60 minutes effectively prevented occlusive thrombosis in experimental monkeys.[1]